• CD47 targeting
  • CD28 targeting
  • How it works

Selective CD47 targeting

A bispecific antibody approach

Step 1 – Guided inhibition

Bispecific antibodies bind Tumor Associated Antigen (TAA) with high affinity and block CD47 upon co-engagement at the cell surface. CD47 expressed by TAA-negative healthy cells is not bound or inhibited.

Selective Cd47 Targeting 1

Created with Biorender

Selective Cd47 Targeting 1

Created with Biorender

Step 2 – Enhanced Antibody Dependent Cellular Phagocytosis (ADCP)

ADCP is induced by antibody Fc (human IgG1) binding to Fc receptors on phagocytes (macrophages or dendritic cells). Tumor cell phagocytosis is increased by the blockade of the CD47-SIRPa interaction, the «don’t eat me signal».

Selective Cd47 Targeting

Created with Biorender

Selective Cd47 Targeting

Created with Biorender

Step 3 – Activation of the adaptive immune response

Dendritic Cells and Macrophages process and cross-present tumor antigens to T lymphocytes leading to the induction anti-tumor immunity and potentially durable responses.

Interested by this approach for your own projects? Partner with us

All drawings have been created by BIORENDER

Back

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn